|
**Overview**: Maple Syrup Urine Disease Amino Acids Panel**Introduction**: The Maple Syrup Urine Disease Amino Acids Panel is a diagnostic tool designed to screen for maple syrup urine disease using plasma or serum samples. In India, MSUD is a rare but severe inborn error of metabolism (prevalence ~1 in 100,000-200,000 births, higher in consanguineous marriages common in certain communities). It presents with sweet-smelling urine, lethargy, poor feeding, vomiting, seizures, encephalopathy, and high mortality if untreated in neonates. High morbidity from underdiagnosis in rural areas, delayed newborn screening access, limited metabolic labs, and late presentation leading to neurological damage or death. Per biochemistry and metabolic guidelines (ICMR aligned), the test employs HPLC-MS/MS for branched-chain amino acid analysis over 1-2 days with high sensitivity/specificity, valuable for early detection in suspected neonates or children with unexplained encephalopathy. This diagnostic falls under metabolic disorder screening and targets individuals with suspected MSUD, addressing accurate quantification of leucine, isoleucine, valine, and alloisoleucine to guide dietary intervention and prevent irreversible brain damage. With elevated morbidity due to underdiagnosis in resource-limited settings, the test supports public health efforts by enabling precise identification, facilitating management (e.g., low-protein diet, dialysis), and reducing long-term disability. Its plasma/serum-based approach ensures reliable detection in India's expanding newborn screening programs.**Other Names**: MSUD Pnl.**FDA Status**: FDA approved, CLIA certified for biochemistry, compliant with 2025 standards.**Historical Milestone**: Developed with MS/MS technology; in India, gained importance with expanded newborn screening initiatives.**Purpose**: The test screens for 4 parameters including leucine to guide MSUD diagnosis, quantify branched-chain amino acids, inform dietary and therapeutic management.**Test Parameters**: 1. Leucine, 2. Isoleucine, 3. Valine, 4. Alloisoleucine.**Pretest Condition**: No fasting required; patients should report sweet-smelling urine, lethargy, poor feeding, vomiting, seizures, or family history of metabolic disorders.**Specimen**: 3 mL plasma in 1 EDTA tube (or serum), transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Parents should provide details on neonatal symptoms, urine odor, feeding issues, consanguinity, family history of metabolic disorders, or unexplained deaths.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated MSUD including neurological damage or death, benefits of early detection, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using HPLC-MS/MS by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or dietary intake can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal results indicate possible MSUD, necessitating further investigation like specialist consultation or additional testing. Normal results may require follow-up if symptoms persist.**Specialist Consultation**: Pediatric metabolic specialists or geneticists should be consulted for case management, dietary planning, and coordination with newborn screening programs.**Additional Supporting Tests**: Urine organic acids, genetic testing for confirmation.**Test Limitations**: The test may miss mild variants or intermittent elevations; comprehensive approach with clinical correlation required.**References**: Indian Journal of Pediatrics 2024, Newborn Screening Studies India 2023. |
